Strategic partnerships Explore collaboration opportunities with large biopharma and CDMO partners (e.g., Porton Advanced, Great Bay Bio) to scale antibody discovery, AI-assisted screening, and manufacturing capabilities for Eureka’s T-cell therapies and antibody programs.

Clinical pipeline focus Leverage Eureka’s preclinical T-cell therapy programs and high-potential partnerships (Novartis collaboration) to position co-development or licensing deals around early-stage assets, accelerating clinical timelines and de-risking for potential buyers.

Early-stage financing Target strategic grant funding and non-dilutive capital similar to prior CIRM support; identify investors and grant opportunities aligned with pediatric liver cancer and intracellular antigen targeting to extend runway for preclinical programs.

Technology enabled Offer joint development around AI-powered antibody discovery and fully-human antibody platforms; propose pilot collaborations with AI-focused biotech firms to enhance hit discovery and reduce time-to-candidate.

Clinical development leverage Position as a partner for late-stage expansion or co-development in liver cancer and hepatoblastoma areas, leveraging existing trials and webinar-driven awareness to attract CROs, manufacturing partners, and access to specialized regulatory pathways.